MX2022013081A - Compuestos para el tratamiento de sars. - Google Patents
Compuestos para el tratamiento de sars.Info
- Publication number
- MX2022013081A MX2022013081A MX2022013081A MX2022013081A MX2022013081A MX 2022013081 A MX2022013081 A MX 2022013081A MX 2022013081 A MX2022013081 A MX 2022013081A MX 2022013081 A MX2022013081 A MX 2022013081A MX 2022013081 A MX2022013081 A MX 2022013081A
- Authority
- MX
- Mexico
- Prior art keywords
- sars
- compounds
- treatment
- covid
- cov
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014501P | 2020-04-23 | 2020-04-23 | |
| US202063120079P | 2020-12-01 | 2020-12-01 | |
| PCT/US2021/019285 WO2021216195A1 (en) | 2020-04-23 | 2021-02-23 | Compounds for the treatment of sars |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013081A true MX2022013081A (es) | 2022-11-10 |
Family
ID=78269813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013081A MX2022013081A (es) | 2020-04-23 | 2021-02-23 | Compuestos para el tratamiento de sars. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230159516A1 (https=) |
| EP (1) | EP4139280A4 (https=) |
| JP (2) | JP2023522990A (https=) |
| KR (1) | KR20230005240A (https=) |
| CN (1) | CN115667209A (https=) |
| AU (1) | AU2021259145A1 (https=) |
| BR (1) | BR112022021381A2 (https=) |
| CA (1) | CA3176370A1 (https=) |
| MX (1) | MX2022013081A (https=) |
| WO (1) | WO2021216195A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| JP2024102382A (ja) * | 2021-05-18 | 2024-07-31 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有する化合物 |
| JP2024522990A (ja) * | 2021-06-02 | 2024-06-25 | エイシア セラピューティクス, インコーポレイテッド | 抗ウイルス薬としてのプロテアーゼ阻害剤 |
| WO2022266363A1 (en) * | 2021-06-16 | 2022-12-22 | The Scripps Research Institute | Protease inhibitors for the treatment of coronavirus infections |
| CN114456211B (zh) * | 2021-09-03 | 2024-03-26 | 中国药科大学 | 一种拟肽类化合物及其制备方法和应用 |
| CN115806570B (zh) * | 2021-11-15 | 2023-09-12 | 南京知和医药科技有限公司 | 一种拟肽衍生物及其药物组合物和用途 |
| US20240228535A1 (en) * | 2022-11-22 | 2024-07-11 | Merck Sharp & Dohme Llc | Protease inhibitors for treating or preventing coronavirus infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| PE20020157A1 (es) * | 1999-12-03 | 2002-02-22 | Agouron Pharma | Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis |
| WO2004093860A1 (en) * | 2003-04-21 | 2004-11-04 | Pfizer Inc. | Inhibitors of sars related coronavirus proteinase |
| AU2004312547A1 (en) * | 2003-12-31 | 2005-07-21 | Taigen Biotechnology | Protease inhibitors |
| WO2006061714A2 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| US20110269834A1 (en) * | 2008-08-21 | 2011-11-03 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for treating respiratory diseases |
| CN107043334B (zh) * | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| CN102838523A (zh) * | 2011-06-23 | 2012-12-26 | 南开大学 | 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途 |
| CA2850003C (en) * | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| CN103130710B (zh) * | 2011-11-29 | 2015-12-16 | 南开大学 | 抗肠病毒71(ev71)己内酰胺醛类化合物及其制备方法和用途 |
| CN106928206B (zh) * | 2015-12-31 | 2022-02-18 | 中国科学院上海药物研究所 | 醛基类化合物及其制法和用途 |
| CN110818691A (zh) * | 2018-08-09 | 2020-02-21 | 中国科学院上海药物研究所 | 酮酰胺类化合物及其制备方法、药物组合物和用途 |
| GB2595975B (en) * | 2020-06-09 | 2022-12-07 | Pardes Biosciences Inc | Inhibitors of cysteine proteases and methods of use thereof |
-
2021
- 2021-02-23 MX MX2022013081A patent/MX2022013081A/es unknown
- 2021-02-23 WO PCT/US2021/019285 patent/WO2021216195A1/en not_active Ceased
- 2021-02-23 KR KR1020227040414A patent/KR20230005240A/ko active Pending
- 2021-02-23 US US17/996,898 patent/US20230159516A1/en active Pending
- 2021-02-23 BR BR112022021381A patent/BR112022021381A2/pt unknown
- 2021-02-23 EP EP21793587.3A patent/EP4139280A4/en active Pending
- 2021-02-23 CN CN202180029527.5A patent/CN115667209A/zh active Pending
- 2021-02-23 JP JP2022564281A patent/JP2023522990A/ja active Pending
- 2021-02-23 AU AU2021259145A patent/AU2021259145A1/en active Pending
- 2021-02-23 CA CA3176370A patent/CA3176370A1/en active Pending
-
2025
- 2025-06-20 JP JP2025104709A patent/JP2025134881A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025134881A (ja) | 2025-09-17 |
| KR20230005240A (ko) | 2023-01-09 |
| EP4139280A4 (en) | 2024-08-07 |
| US20230159516A1 (en) | 2023-05-25 |
| BR112022021381A2 (pt) | 2022-12-06 |
| CN115667209A (zh) | 2023-01-31 |
| JP2023522990A (ja) | 2023-06-01 |
| AU2021259145A1 (en) | 2022-11-10 |
| EP4139280A1 (en) | 2023-03-01 |
| CA3176370A1 (en) | 2021-10-28 |
| WO2021216195A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| CL2019000819A1 (es) | Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| BR112022023187A2 (pt) | Compostos para o tratamento da sars | |
| UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
| DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| MX2017009643A (es) | Composiciones y métodos de uso de inhibidores de tirosina quinasa. | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX387969B (es) | Composiciones y compuestos terapéuticos, y métodos para su uso. | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| UY39863A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
| MX2021012749A (es) | Inhibidor selectivo de la jak1 cinasa. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| WO2022119858A8 (en) | Compounds for the treatment of sars |